RT Journal Article
SR Electronic
T1 iRECIST and atypical patterns of response to immuno-oncology drugs
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP e004849
DO 10.1136/jitc-2022-004849
VO 10
IS 6
A1 Jorge Luis Ramon-Patino
A1 Sabine Schmid
A1 Sally Lau
A1 Lesley Seymour
A1 Pierre-Olivier Gaudreau
A1 Janice Juan Ning Li
A1 Penelope Ann Bradbury
A1 Emiliano Calvo
YR 2022
UL http://jitc.bmj.com/content/10/6/e004849.abstract
AB With the advent of immunotherapy as one of the keystones of the treatment of our patients with cancer, a number of atypical patterns of response to these agents has been identified. These include pseudoprogression, where the tumor initially shows objective growth before decreasing in size, and hyperprogression, hypothesized to be a drug-induced acceleration of the tumor burden. Despite it being >10 years since the first immune-oncology drug was approved, neither the biology behind these paradoxical responses has been well understood, nor their incidence, identification criteria, predictive biomarkers, or clinical impact have been fully described. Immune-based Response Evaluation Criteria in Solid Tumors (iRECIST) guidelines have been published as a revision to the RECIST V.1.1 criteria for use in trials of immunotherapeutics, and the iRECIST subcommittee (of the RECIST Working Group) is working on elucidating these aspects, with data sharing a current major challenge to move forward with this unmet need in immuno-oncology.